Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

TRANSITION THERAPEUTICS INC. T.TTH

"Transition Therapeutics Inc is a product-focused biopharmaceutical company. The Company is engaged in developing therapeutics for disease indications with markets. Its technologies are focused on the treatment of Alzheimer's disease and diabetes."


TSX:TTH - Post by User

Comment by deninsaskon Nov 26, 2007 6:03pm
81 Views
Post# 13870023

RE: Blood Test Might Spot Alzheimer''''s Early

RE: Blood Test Might Spot Alzheimer''''s Early Thanks for the great article. " "Because we don't have a marker that predicts [Alzheimer's] right now, such a trial is almost prohibitively expensive," he said -- askretka....."TTH's and Elan's phase III costs just got a whole lot cheaper and TTH's cost to get their 50% stake just got a lot cheaper as well I would guess." ........"This new alzheimer's blood test will make the screening process for potential patients a lot faster and cheaper." That would be great al....... Recall that Elan and Transition set up the $200 Million WW Collaberation in such a way that Transition will not have to put up a single dollar of their own to complete the Trials. Milestone and Progress payments will be sufficient to cover all of Transitions share of the developmental costs. Of course the $15 million Upfront Payment from Elan was not included in the calculations. That goes straight into the Transition Vault. So if Transition elects to increase its position from 30% up to 50% (Dr. Cruz again reiterated that that is their intention) it could very well be as you say, Much Cheaper for both Transition and Elan. It is my understanding that the testing on these blood tests is moving along very quickly. Transition and Elan are using all sorts of bio-markers to trace AZD-103 in the Human Body. To be able to have one to help with enrolling patients used in conjunction with the current standard testing would speed things up a lot!! Good luck all.
Bullboard Posts